JP2012507030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012507030A5 JP2012507030A5 JP2011533853A JP2011533853A JP2012507030A5 JP 2012507030 A5 JP2012507030 A5 JP 2012507030A5 JP 2011533853 A JP2011533853 A JP 2011533853A JP 2011533853 A JP2011533853 A JP 2011533853A JP 2012507030 A5 JP2012507030 A5 JP 2012507030A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- patient
- complex
- predetermined threshold
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 20
- 102100032442 Protein S100-A8 Human genes 0.000 claims 15
- 206010053159 Organ failure Diseases 0.000 claims 9
- 206010040070 Septic Shock Diseases 0.000 claims 8
- 230000004768 organ dysfunction Effects 0.000 claims 8
- 230000036303 septic shock Effects 0.000 claims 8
- 206010040047 Sepsis Diseases 0.000 claims 7
- 239000012472 biological sample Substances 0.000 claims 7
- 238000004393 prognosis Methods 0.000 claims 5
- 238000003018 immunoassay Methods 0.000 claims 4
- 108010048233 Procalcitonin Proteins 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 102100029599 Advanced glycosylation end product-specific receptor Human genes 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 101001061840 Homo sapiens Advanced glycosylation end product-specific receptor Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 101800001904 NT-proBNP Proteins 0.000 claims 1
- 102400001263 NT-proBNP Human genes 0.000 claims 1
- 102100032420 Protein S100-A9 Human genes 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000000066 myeloid cell Anatomy 0.000 claims 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000004910 pleural fluid Anatomy 0.000 claims 1
- 238000010837 poor prognosis Methods 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/259,596 US8283131B2 (en) | 2008-10-28 | 2008-10-28 | Methods and kits for the rapid determination of patients at high risk of death during severe sepsis and septic shock |
| US12/259,596 | 2008-10-28 | ||
| US15852009P | 2009-03-09 | 2009-03-09 | |
| US61/158,520 | 2009-03-09 | ||
| PCT/IB2009/007493 WO2010049818A1 (en) | 2008-10-28 | 2009-10-27 | Methods and kits for the rapid determination of patients at high risk of death during severe sepsis and septic shock |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012507030A JP2012507030A (ja) | 2012-03-22 |
| JP2012507030A5 true JP2012507030A5 (enExample) | 2012-11-29 |
| JP5619016B2 JP5619016B2 (ja) | 2014-11-05 |
Family
ID=41572522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533853A Expired - Fee Related JP5619016B2 (ja) | 2008-10-28 | 2009-10-27 | 重症敗血症及び敗血症性ショック中の死亡の危険性が高い患者を迅速に決定するための方法及びキット |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110287433A1 (enExample) |
| EP (1) | EP2350646B1 (enExample) |
| JP (1) | JP5619016B2 (enExample) |
| CN (1) | CN102257387A (enExample) |
| WO (1) | WO2010049818A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2556771T3 (es) * | 2009-01-19 | 2016-01-20 | bioMérieux S.A. | Procedimientos para determinar la susceptibilidad de contraer una infección nosocomial en un paciente y para establecer un pronóstico de evolución de un síndrome séptico |
| US9945873B2 (en) * | 2011-01-21 | 2018-04-17 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient by measuring endocan levels in blood |
| FR2970975B1 (fr) * | 2011-01-27 | 2016-11-04 | Biomerieux Sa | Procede et kit pour determiner in vitro le statut immunitaire d'un individu |
| CN102636645A (zh) * | 2012-04-24 | 2012-08-15 | 广州吉赛生物科技有限公司 | 一种sTERM-1酶联免疫检测试剂盒及其方法 |
| US10815526B2 (en) | 2013-11-25 | 2020-10-27 | Children's Hospital Medical Center | Temporal pediatric sepsis biomarker risk model |
| DK3117030T3 (da) * | 2014-03-14 | 2022-06-27 | Robert E W Hancock | Diagnosticering af sepsis |
| KR101929772B1 (ko) * | 2016-11-02 | 2018-12-17 | 연세대학교 산학협력단 | 패혈증 진단을 위한 정보를 제공하는 방법 및 이를 이용한 키트 |
| CN108982844B (zh) * | 2018-08-17 | 2021-09-24 | 北京市心肺血管疾病研究所 | 血清S100a8/9复合体水平在急性心肌梗死诊断及预后判断中的应用 |
| US20230151434A1 (en) * | 2020-04-07 | 2023-05-18 | The Wistar Institute Of Anatomy And Biology | Reawakening of dormant tumor cells by modified lipids derived from stress activated neutrophils |
| CN114606308A (zh) * | 2022-01-26 | 2022-06-10 | 江门市中心医院 | 脓毒症ards的预后与治疗标志物 |
| CN118717994A (zh) * | 2024-07-26 | 2024-10-01 | 浙江大学医学院附属第一医院(浙江省第一医院) | 肝硬化中S100A8/A9诱导NK细胞产生IFNγ的应用 |
| CN119492874A (zh) * | 2024-10-30 | 2025-02-21 | 首都医科大学附属北京儿童医院保定医院 | S100a8/a9在评估感染性疾病病情严重程度中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1297922A (zh) * | 1999-11-26 | 2001-06-06 | 上海博道基因技术有限公司 | 一种多肽－人钙结合s100蛋白21和编码该多肽的多核苷酸 |
| DE50108027D1 (de) * | 2001-12-04 | 2005-12-15 | Brahms Ag | Verwendung der Glycin-N-Acyl-Transferase (GNAT) für die Diagnose von Entzündungserkrankungen und Sepsis |
| WO2004046181A1 (de) * | 2002-11-20 | 2004-06-03 | B.R.A.H.M.S Aktiengesellschaft | Sandwich-immunoassay zur bestimmung bon proanp-teilpeptiden |
| US7645733B2 (en) * | 2003-09-29 | 2010-01-12 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
| US7659087B2 (en) * | 2004-07-23 | 2010-02-09 | Aspenbio Pharma, Inc. | Methods and devices for diagnosis of appendicitis |
| TR200700896T1 (tr) * | 2004-07-23 | 2007-04-24 | Aspenbio, Inc. | Apandisit teşhisine ilişkin yöntem ve cihazlar |
| US20070092911A1 (en) * | 2005-10-03 | 2007-04-26 | Buechler Kenneth F | Methods and compositions for diagnosis and /or prognosis in systemic inflammatory response syndromes |
| CN101193622A (zh) * | 2005-06-09 | 2008-06-04 | 比奥里波克斯公司 | 治疗炎性疾病的方法和组合物 |
| EP1950310A1 (en) * | 2007-01-23 | 2008-07-30 | Charite-Universitätsmedizin Berlin | Method for risk prediction of a postoperative sepsis in a human |
| DE102007009751A1 (de) * | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
| EP2085486A1 (en) * | 2008-02-01 | 2009-08-05 | Assistance Publique - Hopitaux de Paris | Methods and kits for the rapid determination of patients at high risk of death during septic shock |
| US8283131B2 (en) * | 2008-10-28 | 2012-10-09 | Assistance Publique-Hopitaux De Paris | Methods and kits for the rapid determination of patients at high risk of death during severe sepsis and septic shock |
-
2009
- 2009-10-27 EP EP09760590.1A patent/EP2350646B1/en not_active Not-in-force
- 2009-10-27 US US13/126,575 patent/US20110287433A1/en not_active Abandoned
- 2009-10-27 WO PCT/IB2009/007493 patent/WO2010049818A1/en not_active Ceased
- 2009-10-27 CN CN2009801518443A patent/CN102257387A/zh active Pending
- 2009-10-27 JP JP2011533853A patent/JP5619016B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012507030A5 (enExample) | ||
| HK1253858A1 (zh) | 用於肾损伤和肾衰竭的诊断及预後的方法和组合物 | |
| CN107003320B (zh) | 慢性肾脏疾病的快速进展的生物标志物 | |
| EP2671083A1 (en) | Methods of prognosis and diagnosis in chronic heart failure | |
| JP2015503920A (ja) | 乳癌の予測および診断のためのバイオマーカー | |
| JP2015517801A5 (enExample) | ||
| JP2014509515A5 (enExample) | ||
| JP2011232218A (ja) | 動脈硬化の評価法 | |
| CN102257387A (zh) | 严重脓毒病和败血性休克期间用于快速确定死亡高风险病人的方法和试剂盒 | |
| KR20210049829A (ko) | 심방 세동의 사정에서 및 뇌졸중의 예측을 위한 순환하는 fgfbp-1 (섬유모세포 성장 인자-결합 단백질 1) | |
| EP2372364A1 (en) | Biomarker for pulmonary hypertension | |
| AU2014343709B2 (en) | Biomarkers and methods for progression prediction for chronic kidney disease | |
| JP6192122B2 (ja) | 結腸直腸癌診断および予測のためのバイオマーカー | |
| KR20220066149A (ko) | 패혈증 관리 | |
| US10557860B2 (en) | Circulating pulmonary hypertension biomarker | |
| JP7162104B2 (ja) | 糖尿病性腎症の早期病態の特異的な診断を可能とする検査方法 | |
| WO2010118855A1 (en) | Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin | |
| Villalba et al. | The N-terminal pro brain natriuretic peptide is the best predictor of mortality during hospitalization in patients with low risk of sepsis-related organ failure | |
| CN113939741B (zh) | HFpEF的IGFBP7比率 | |
| CN111770935A (zh) | 特异性识别APP669-x的N末端的抗体及免疫测定法 | |
| EP3446124A1 (en) | Soluble st2 for the identification of progressors to lvh in the general population | |
| WO2021024856A1 (ja) | 間質性肺炎のタンパク質診断バイオマーカー | |
| EP2766732B1 (en) | Methods and kits for detecting cardiac remodeling in subjects without clinical signs of heart failure | |
| EP3279667A1 (en) | Cardiac troponin i and copeptin as biomarkers for short-term mortality in acute exacerbation of chronic obstructive pulmonary disease (aecopd) | |
| CN115836227A (zh) | 利用尿样诊断肾病的组合物 |